Orexo AB (LTS:0H19) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H19 Orexo AB LTS:0H19
48 GF Score
Price kr24.68
GF Value kr6.31
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orexo AB FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0H19
48GF Score
Orexo AB LTS:0H19
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orexo AB (LTS:0H19) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr24.68 is trading 291% above its estimated GF Value™ of kr6.31. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for LTS:0H19:

  • FFO:
  • GF Value™: kr6.31 vs. price of kr24.68 (291% above fair value)
  • GF Score™: 48/100 with 8 warning signs

No single metric tells the full story. See the LTS:0H19 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
48GF Score

Get the complete analysis for LTS:0H19

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr24.68
Price
kr6.31
GF Value